NEW YORK ( TheStreet) -- Cleveland BioLabs ( CBLI), Derma Sciences ( DSCI), Poniard Pharmaceuticals ( PARD), NeurogesX ( NGSX) and MediciNova ( MNOV) will release their latest quarterly earnings today.

Some of the above stocks recorded exponential gains during the past one year, much more than its major peers. For instance, Derma Sciences and Poniard Pharmaceuticals have accumulated 171% and 186%, respectively, while bigger names such as Johnson & Johnson ( JNJ) and Pfizer ( PFE) have gained 10% and 11%, respectively.
5. Cleveland BioLabs is a biotechnology company developing biodefense, tissue protection and cancer treatment drugs conceptualized on the basis of modulation of cell death for therapeutic benefit. The company's products belong to two primary families of compounds: protectans and curaxins. Protectans are drug candidates that protect healthy tissue from acute stress such as radiation, chemotherapy, and ischemia, while Curaxins are being developed as anticancer agents that could act as mono-therapy drugs, or in combination with other existing anticancer therapies.

Net loss per share for the first quarter is forecast at 1-cent on sales of $4.6 million, compared to net loss of 14 cents per share on sales of $4.2 million recorded during first quarter 2009, according to analysts polled by Bloomberg.

The company recently announced that Protectan--its unlicensed drug--proved effective in treating radiation sickness up to 48 hours after initial exposure. Although the drug is awaiting approval, the company believes that there are no licensed drugs in this space. The company has adequate inventory of the drug to treat approximately 1,000 patients.

Of the three analysts covering the stock, 67% recommend a buy while the remaining recommend a hold. There are no sell ratings on the stock. Analysts polled by Bloomberg expect the stock to gain an average 22% to $9 in value from current levels. Additionally, the stock has more than doubled during the past one year.

4. Derma Sciences is a specialty medical device/pharmaceutical company engaged in the manufacture, marketing and sale of three dermatological related product lines: wound care, wound closure and specialty securement devices, and skin care.

Net loss for the fourth quarter is forecast at $0.5 million on sales of $15.7 million, compared to net income of $0.04 million on sales of $13.65 million recorded during fourth-quarter 2009, according to analysts polled by Bloomberg. Loss per share is seen at 39 cents for 2010, up from 23 cents per share reported during 2009. For 2011, loss per share is likely to narrow to 27 cents, analysts foresee.

The company recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its patent-pending MEDIHONEY Gel Wound and Burn Dressing. This is the fourth product in the expanding MEDIHONEY franchise, which will strengthen brand leadership positioning. The product will be launched at the major annual wound conference this spring.

Of the two analysts covering the stock, one recently upgraded it from underperform to neutral, while the other rated the stock outperform, raising its price target from $13 to $25, or an upside of 171% over current levels. Additionally, the stock has accumulated 80% during the past one year.

3. Poniard Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of cancer therapeutics. The company's lead product candidate is Picoplatin, an intravenous platinum-based chemotherapeutic designed to treat solid tumors that are resistant to existing platinum-based cancer therapies.

Analysts polled by Bloomberg expect loss per share of 69 cents for 2010, down from $1.31 per share reported during 2009. For 2011, loss per share is likely to contract to 41 cents, analysts foresee.

The company recently announced the receipt of Clinical Trial Application (CTA) approval from the Chinese State Food and Drug Administration (SFDA) to conduct two Phase III clinical studies of Picoplatin, its lead product candidate in the treatment of second-line small cell lung cancer (SCLC) and second-line ovarian cancer in China.

Of the two analysts covering the stock, 50% recommend a buy, while the remaining rate a hold. There are no sell ratings on the stock. Analysts polled by Bloomberg expect the stock to gain an average 186% to $1 in value from current levels.

2. NeurogesX is a biopharmaceutical company developing and commercializing pain management therapies. The company is assembling a portfolio of pain management product candidates based on known chemical entities. The company is initially focusing on the management of chronic peripheral neuropathic pain conditions.

Net loss for the fourth quarter is forecast at $14.1 million on sales of $2.4 million, compared to a net loss of $5.1 million on sales of $1.9 million recorded during fourth-quarter 2009, according to analysts polled by Bloomberg. Loss per share is seen at $2.50 for 2010, as against a loss of $1.24 per share reported during 2009. For 2011, earnings per share are likely to narrow to $2.30, analysts anticipate

Of the four analysts covering the stock, 75% recommend a buy, while the remaining advise a hold. There are no sell ratings on the stock. Analysts polled by Bloomberg expect the stock to gain an average 218% to $11 in value from current levels. The stock is currently trading at its 52-week highs.

1. MediciNova is a Japan-based biopharmaceutical company engaged in the acquisition and development of low molecular pharmaceutical products for diseases with no effective treatment, mainly in the U.S. market. The company acquires pharmaceuticals from pharmaceutical companies in Japan and European countries.

Net loss for the fourth quarter is forecast at $5.1 million compared to net income of $5.9 million during fourth-quarter 2009, according to analysts polled by Bloomberg. Loss per share is seen at $1.62 for 2010, as opposed to $1.68 per share reported during 2009. For 2011, loss is likely to increase to $1.89 per share, analysts envisage. The company is expected to earn revenue of $50.2 million during 2014.

Earlier this month, the company signed a letter of intent regarding for forming a joint venture with Zhejiang Medicine Co. to develop and commercialize MN-221 in China. MN-221 is currently in Phase II development for the treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) exacerbations in the U.S.

All the five analysts covering the stock recommend a buy on it. There are no sell ratings on the stock. Analysts polled by Bloomberg expect the stock to gain an average 226% to $11.72 in value from current levels.

>>To see these stocks in action, visit the 5 Health Care Stocks With Upside portfolio on Stockpickr.